269 related articles for article (PubMed ID: 31173466)
41. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
42. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.
Kratz CP; Schubbert S; Bollag G; Niemeyer CM; Shannon KM; Zenker M
Cell Cycle; 2006 Aug; 5(15):1607-11. PubMed ID: 16921267
[TBL] [Abstract][Full Text] [Related]
43. Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient.
Baquedano Lobera I; Izquierdo Álvarez S; Oliván Del Cacho MJ
BMC Pediatr; 2019 Apr; 19(1):92. PubMed ID: 30953504
[TBL] [Abstract][Full Text] [Related]
44. [Noonan syndrome can be diagnosed clinically and through molecular genetic analyses].
Henningsen MK; Jelsig AM; Andersen H; Brusgaard K; Ousager LB; Hertz JM
Ugeskr Laeger; 2015 Aug; 177(32):V12140755. PubMed ID: 26321587
[TBL] [Abstract][Full Text] [Related]
45. The recurrent PPP1CB mutation p.Pro49Arg in an additional Noonan-like syndrome individual: Broadening the clinical phenotype.
Bertola D; Yamamoto G; Buscarilli M; Jorge A; Passos-Bueno MR; Kim C
Am J Med Genet A; 2017 Mar; 173(3):824-828. PubMed ID: 28211982
[TBL] [Abstract][Full Text] [Related]
46. Senescence in RASopathies, a possible novel contributor to a complex pathophenoype.
Engler M; Fidan M; Nandi S; Cirstea IC
Mech Ageing Dev; 2021 Mar; 194():111411. PubMed ID: 33309600
[TBL] [Abstract][Full Text] [Related]
47. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
[TBL] [Abstract][Full Text] [Related]
48. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
49. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
50. ADA2 deficiency in a patient with Noonan syndrome-like disorder with loose anagen hair: The co-occurrence of two rare syndromes.
Akgun-Dogan O; Simsek-Kiper PO; Taskiran E; Lissewski C; Brinkmann J; Schanze D; Göçmen R; Cagdas D; Bilginer Y; Utine GE; Zenker M; Ozen S; Tezcan İ; Alikasifoglu M; Boduroğlu K
Am J Med Genet A; 2019 Dec; 179(12):2474-2480. PubMed ID: 31584751
[TBL] [Abstract][Full Text] [Related]
51. Acute lymphoblastic leukemia in the context of RASopathies.
Cavé H; Caye A; Strullu M; Aladjidi N; Vignal C; Ferster A; Méchinaud F; Domenech C; Pierri F; Contet A; Cacheux V; Irving J; Kratz C; Clavel J; Verloes A
Eur J Med Genet; 2016 Mar; 59(3):173-8. PubMed ID: 26855057
[TBL] [Abstract][Full Text] [Related]
52. Dermatological manifestations, management, and care in RASopathies.
Kavamura MI; Leoni C; Neri G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):452-458. PubMed ID: 36541891
[TBL] [Abstract][Full Text] [Related]
53. Molecular Genetics of Noonan Syndrome and RASopathies.
Liao J; Mehta L
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):435-446. PubMed ID: 31115195
[TBL] [Abstract][Full Text] [Related]
54. RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR.
Brand K; Kentsch H; Glashoff C; Rosenberger G
Hum Mutat; 2014 Nov; 35(11):1372-81. PubMed ID: 25178484
[TBL] [Abstract][Full Text] [Related]
55. Diagnosis of Noonan syndrome and related disorders using target next generation sequencing.
Lepri FR; Scavelli R; Digilio MC; Gnazzo M; Grotta S; Dentici ML; Pisaneschi E; Sirleto P; Capolino R; Baban A; Russo S; Franchin T; Angioni A; Dallapiccola B
BMC Med Genet; 2014 Jan; 15():14. PubMed ID: 24451042
[TBL] [Abstract][Full Text] [Related]
56. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.
Athota JP; Bhat M; Nampoothiri S; Gowrishankar K; Narayanachar SG; Puttamallesh V; Farooque MO; Shetty S
BMC Med Genet; 2020 Mar; 21(1):50. PubMed ID: 32164556
[TBL] [Abstract][Full Text] [Related]
57. The heart in RASopathies.
Delogu AB; Limongelli G; Versacci P; Adorisio R; Kaski JP; Blandino R; Maiolo S; Monda E; Putotto C; De Rosa G; Chatfield KC; Gelb BD; Calcagni G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):440-451. PubMed ID: 36408797
[TBL] [Abstract][Full Text] [Related]
58. Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
Schubbert S; Bollag G; Shannon K
Curr Opin Genet Dev; 2007 Feb; 17(1):15-22. PubMed ID: 17208427
[TBL] [Abstract][Full Text] [Related]
59. Noonan syndrome and systemic lupus erythematosus in a patient with a novel KRAS mutation.
Leventopoulos G; Denayer E; Makrythanasis P; Papapolychroniou C; Fryssira H
Clin Exp Rheumatol; 2010; 28(4):556-7. PubMed ID: 20810036
[TBL] [Abstract][Full Text] [Related]
60. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Tajan M; Paccoud R; Branka S; Edouard T; Yart A
Endocr Rev; 2018 Oct; 39(5):676-700. PubMed ID: 29924299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
